Natco Pharma
BSE: 524816 | NSE: NATCOPHARM | ISIN: INE987B01018 | Pharmaceuticals
 |
Profit & Loss account of Natco Pharma |
------------------- in Rs. Cr. ------------------- |
| Mar '05 | Mar '06 | Mar '07 | Mar '08 | Mar '09 | ||||||
|
||||||||||
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||||||
|
||||||||||
| Income | ||||||||||
| Sales Turnover | 171.60 | 170.12 | 194.33 | 237.75 | 275.93 | |||||
| Excise Duty | 5.61 | 7.63 | 8.45 | 6.87 | 4.10 | |||||
| Net Sales | 165.99 | 162.49 | 185.88 | 230.88 | 271.83 | |||||
| Other Income | 3.13 | 19.84 | 15.90 | 13.01 | 9.35 | |||||
| Stock Adjustments | -0.85 | 1.60 | 6.25 | 4.05 | 7.10 | |||||
| Total Income | 168.27 | 183.93 | 208.03 | 247.94 | 288.28 | |||||
| Expenditure | ||||||||||
| Raw Materials | 69.45 | 75.08 | 83.36 | 96.42 | 101.31 | |||||
| Power & Fuel Cost | 6.41 | 7.74 | 10.13 | 11.02 | 15.24 | |||||
| Employee Cost | 18.57 | 23.49 | 25.30 | 30.48 | 37.17 | |||||
| Other Manufacturing Expenses | 4.33 | 3.96 | 4.68 | 5.65 | 6.98 | |||||
| Selling and Admin Expenses | 39.59 | 24.52 | 23.36 | 28.17 | 38.86 | |||||
| Miscellaneous Expenses | 3.50 | 4.39 | 5.02 | 6.31 | 8.92 | |||||
| Preoperative Exp Capitalised | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Total Expenses | 141.85 | 139.18 | 151.85 | 178.05 | 208.48 | |||||
| Mar '05 | Mar '06 | Mar '07 | Mar '08 | Mar '09 | ||||||
|
||||||||||
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||||||
|
||||||||||
| Operating Profit | 23.29 | 24.91 | 40.28 | 56.88 | 70.45 | |||||
| PBDIT | 26.42 | 44.75 | 56.18 | 69.89 | 79.80 | |||||
| Interest | 13.40 | 8.03 | 6.61 | 9.73 | 15.05 | |||||
| PBDT | 13.02 | 36.72 | 49.57 | 60.16 | 64.75 | |||||
| Depreciation | 5.84 | 6.64 | 7.61 | 8.59 | 10.35 | |||||
| Other Written Off | 7.32 | 3.61 | 2.54 | 0.00 | 0.00 | |||||
| Profit Before Tax | -0.14 | 26.47 | 39.42 | 51.57 | 54.40 | |||||
| Extra-ordinary items | 1.41 | -0.25 | 0.19 | -1.65 | -1.01 | |||||
| PBT (Post Extra-ord Items) | 1.27 | 26.22 | 39.61 | 49.92 | 53.39 | |||||
| Tax | -0.88 | 2.43 | 9.15 | 9.86 | 10.63 | |||||
| Reported Net Profit | 1.56 | 23.79 | 30.46 | 40.05 | 42.74 | |||||
| Total Value Addition | 72.40 | 64.10 | 68.49 | 81.63 | 107.18 | |||||
| Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Equity Dividend | 0.00 | 3.37 | 3.40 | 3.43 | 3.51 | |||||
| Corporate Dividend Tax | 0.00 | 0.47 | 0.48 | 0.58 | 0.60 | |||||
| Per share data (annualised) | ||||||||||
| Shares in issue (lakhs) | 261.61 | 271.74 | 276.45 | 280.41 | 280.41 | |||||
| Earning Per Share (Rs) | 0.60 | 8.76 | 11.02 | 14.28 | 15.24 | |||||
| Equity Dividend (%) | 0.00 | 12.50 | 12.00 | 12.50 | 12.50 | |||||
| Book Value (Rs) | 43.44 | 54.35 | 65.16 | 78.17 | 91.97 | |||||
| ||||||||||
| Source : Religare Technova | ||||||||||
| Explore Natco Pharma connections | ||||||||||
| ||||||||||
